24. December 2017 The preparation of amorphous solid dispersions (ASDs) is a well-established strategy for formulating active pharmaceutical ingredients by embedding them in…
04. December 2017
Abstract
Fused deposition modelling (FDM) 3D printing (3DP) is a revolutionary technology with the potential to transform drug product design in both the pre-clinical and clinical arena. The objective…
27. October 2017 The primary aim of this study was to identify pharmaceutically acceptable amorphous polymers for producing 3D printed tablets of a model drug, haloperidol,…
24. October 2017 Today CPhI worldwide is opening the doors to about 40.000 visitors from the pharmaceutical industry. It is the event for pharmaceutical excipient…
19. October 2017
MIDLAND, Mich - October 18, 2017 - With decades of technical and industry expertise, Dow Pharma Solutions – a business unit of the DowDuPont Specialty Products Division – addresses the toughest challenges…
12. October 2017 Solid dispersion formulation is a promising method to maintain in vivo drug solubility and to improve drug efficacy. However, the exact drug stabilization…
28. July 2017
Abstract
The objective of the current study was to develop an amorphous solid dispersion for a high melting point compound, griseofulvin (GRF), with an enhanced solubility and a controlled release pattern…
26. June 2017 Objectives Mesoporous silicas (SLC) have demonstrated considerable potential to improve bioavailability of poorly soluble drugs by facilitating rapid…
16. May 2017 Abstract The aim of this study was to manufacture 3D printed tablets (printlets) from enteric polymers by single filament fused deposition modeling (FDM) 3D…
12. March 2017 New possibilities using AFFINISOL™ excipients Exploring a platform of tailored polymers for solubility enhancement AFFINISOL™ polymers are…